What Feldan Therapeutics does

Feldan Therapeutics is a clinical-stage biotech company headquartered in Quebec City, Canada, developing therapeutics based on intracellular delivery of biological cargo. Its core asset is the Feldan Shuttle, a proprietary peptide-based platform that enables safe, rapid, and efficient endosomal escape and delivery of antisense oligonucleotides (ASOs), proteins, CRISPR nucleases, transcription factors, and antibodies into cells, unlocking intracellular targets otherwise inaccessible to therapeutic molecules. The platform is applicable across both ex vivo and in vivo settings and has been validated in peer-reviewed Nature and Nature Communications publications.

Feldan translates the platform into a focused pipeline. Its lead candidate, FLD-103, is a non-surgical intralesional treatment for basal cell carcinoma, the most common skin cancer, and is currently in a Phase 1/2a clinical trial running across Quebec and Sydney, Australia. Its second candidate, FLD-201, is an inhaled therapy targeting mucus-driven pulmonary diseases including non-cystic fibrosis bronchiectasis (NCFB) and chronic bronchitis, currently in preclinical development. The platform's third commercial vector is an exclusive 2018 license to GC LabCell for NK cell-based cancer immunotherapy.

The company is pre-revenue, with economics expected to come from a combination of licensing agreements, milestone payments, royalties, and direct commercialization of approved products. Its go-to-market approach relies on enterprise partnerships with pharmaceutical companies (Amgen, Takeda, Sanofi, GSK, Janssen), strategic licensing deals (GC LabCell), and non-dilutive grant funding from Canadian federal programs (NSERC, NRC IRAP, CQDM) and disease foundations (Cystic Fibrosis Foundation, NIH SCGE). As of late 2024, Feldan has raised approximately US$35.3 million in disclosed equity across its Series A and Series B rounds, with Genesys Capital and Fonds de solidarité FTQ co-leading the most recent US$21M Series B completed in September 2024.

Name

Feldan Therapeutics

Legal name

Feldan Therapeutics, Inc.

Website

https://feldan.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Feldan Therapeutics is a clinical-stage biotech developing intracellular therapeutics based on its proprietary Feldan Shuttle peptide delivery platform, with lead candidate FLD-103 in Phase 1/2a trials for non-surgical basal cell carcinoma treatment and preclinical pulmonary programs.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals / Intracellular Delivery Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes) (HLAAADAD)

akta.pro secondary industries

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH)

Keywords

• Intracellular drug delivery
• Peptide-based therapeutics
• Antisense oligonucleotide delivery
• Biopharmaceutical development
• CRISPR delivery technology

Headquarters

HQ city

Quebec

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Therapeutic Product Development: Pre-revenue clinical-stage biotech developing proprietary therapeutics. Revenue will come from product sales upon regulatory approval. Currently advancing FLD-103 for BCC through clinical trials.
2. Technology Licensing: Licensing Feldan Shuttle technology to partners for specific therapeutic applications. GC LabCell licensed the technology for NK cell-based cancer immunotherapy development, receiving milestone payments and royalties on commercialized products.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Feldan Therapeutics develops and commercializes the Feldan Shuttle, a proprietary peptide-based intracellular delivery technology that enables therapeutic cargo (antisense oligonucleotides, proteins, CRISPR nucleases, transcription factors, antibodies) to escape endosomes and reach intracellular targets. The company is advancing therapeutic candidates including FLD-103, a non-surgical intralesional treatment for basal cell carcinoma in Phase 1/2a trials, and FLD-201, an inhaled therapy for mucus-driven pulmonary diseases in preclinical development. The technology is also licensed to pharmaceutical partners such as GC LabCell for NK cell-based cancer immunotherapy.

Product overview

Feldan Therapeutics is a clinical-stage biotech company operating as a single-platform developer: its proprietary Feldan Shuttle peptide-based technology is the core enabler, applied across a portfolio of therapeutic programs. The product portfolio consists of the Feldan Shuttle platform and two named pipeline candidates — FLD-103 (an intralesional non-surgical treatment for basal cell carcinoma in Phase 1/2a clinical trials) and FLD-201 (an inhaled therapy for mucus-driven lung diseases in preclinical development). The Feldan Shuttle enables intracellular delivery of antisense oligonucleotides, proteins, and CRISPR nucleases, allowing previously inaccessible intracellular targets to be addressed in skin and lung diseases.

Differentiator

Problem solved

Functional benefit

Products and services

• Feldan Shuttle Platform A proprietary peptide-based intracellular delivery technology that enables safe, rapid, and efficient local delivery of antisense oligonucleotides (ASO), proteins, CRISPR nucleases, and other therapeutic cargo into cells, unlocking intracellular targets that are otherwise beyond reach. Applicable for ex vivo and in vivo use across skin and lung disease applications. Licensed to partners including GC LabCell.
• FLD-103 A non-surgical intralesional treatment for basal cell carcinoma (BCC), the most common form of skin cancer. FLD-103 is delivered directly into tumor lesions using the Feldan Shuttle platform and is in Phase 1/2a clinical trials.
• FLD-201 An inhaled therapy targeting mucus-driven lung diseases such as non-cystic fibrosis bronchiectasis (NCFB) and chronic bronchitis. FLD-201 is in preclinical development and leverages the Feldan Shuttle technology for pulmonary delivery to airway epithelial cells.

Quantifiable outcome

• Phase 1/2a clinical trial initiated for FLD-103 in basal cell carcinoma (October 2024)

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered major.

• TransBIOTechmajorStrategic or Co-development Partner · 12 March 2026NSERC-funded collaboration (CA$450,000) for development of novel intralesional therapeutic approaches targeting tumor lesions. TransBIOTech conducts in vivo experiments. Nearly decade-long partnership supporting Feldan Shuttle development.
• CQDMmajorStrategic or Co-development Partner · 18 April 2023CQDM funded $503,779 project to optimize lung drug delivery platform. Combined with Amgen and Feldan contributions totaling $1,427,757 for collaborative development.
• AmgenmajorStrategic or Co-development Partner · 18 April 2023Collaborating with CQDM and Feldan on lung disease drug delivery technology optimization. Part of broader Quantum Leap project for Feldan Shuttle enhancement. Amgen Ventures also an investor.
• University of Iowa (Dr. Paul McCray)majorStrategic or Co-development Partner · 28 October 2019Long-term collaboration on lung delivery research. Dr. McCray is expert in respiratory cell biology and cystic fibrosis treatment. Joint NIH-funded projects worth $4M for CRISPR delivery to airway epithelia.
• TakedamajorStrategic or Co-development Partner · 4 June 2019Joined Quantum Leap project led by CQDM and Feldan. Japanese pharmaceutical company participating in consortium to improve Feldan Shuttle technology.
• GC LabCellmajorOEM/ Whitelabel/ Licensing Partner · 27 June 2018Exclusive license agreement for Feldan Shuttle in NK cell-based cancer immunotherapy development. GC LabCell developing enhanced NK cells for adoptive cell therapy. Feldan receives milestone payments and royalties on commercialized products.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Acuitas Therapeutics: Developer of lipid nanoparticle (LNP) delivery technology for nucleic acid therapeutics including mRNA, siRNA, and CRISPR cargo. Direct comparable as a non-viral intracellular delivery platform enabling therapeutic payloads to reach intracellular targets.
• Genevant Sciences: LNP-based nucleic acid delivery technology company developing RNA-based therapeutics. Directly comparable as a platform delivery company monetizing technology through partnerships and licensing across multiple therapeutic areas.
• Generation Bio: Developer of non-viral lipid nanoparticle delivery platform for DNA and RNA therapeutics targeting genetic diseases. Comparable as a non-viral delivery platform company addressing intracellular delivery challenges for nucleic acid cargo.
• Arcturus Therapeutics: Clinical-stage mRNA medicines company with proprietary LNP delivery technology and pipeline spanning vaccines, protein replacement, and rare diseases. Comparable as a nucleic acid delivery and therapeutics company with similar platform-plus-product model.
• Verve Therapeutics: Clinical-stage in vivo gene editing company developing single-course treatments for cardiovascular disease using base editing. Comparable as a company using novel delivery approaches to enable intracellular gene editing therapeutics.
• Beam Therapeutics: Clinical-stage base editing company developing precision genetic medicines delivered via LNPs and electroporation. Comparable in its reliance on non-viral delivery approaches to enable intracellular editing therapeutics.

Broad incumbents

• BioNTech: Global mRNA therapeutics and LNP delivery powerhouse with validated COVID-19 vaccine franchise and broad oncology pipeline. Comparable as a large-scale mRNA delivery and therapeutics company, though far broader and more commercially advanced than Feldan.
• Moderna: Commercial-stage mRNA medicines company with proprietary LNP delivery platform and broad pipeline across infectious disease, oncology, and rare diseases. Comparable as a leading nucleic acid delivery platform, though operating at vastly larger scale.
• Translate Bio (Sanofi): Acquired by Sanofi in 2021, Translate Bio developed mRNA therapeutics with inhaled delivery for cystic fibrosis and other pulmonary diseases. Comparable to Feldan's pulmonary delivery ambitions for FLD-201 and CF application.

Emerging players

• ReCode Therapeutics: Clinical-stage genetic medicines company with proprietary lipid nanoparticle delivery technology targeting lung and liver diseases including cystic fibrosis and primary ciliary dyskinesia. Closely comparable to Feldan's pulmonary delivery focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds8 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Feldan Therapeutics